In the past few years, many novel drugs such as sodium-glucose cotransporter-2 inhibitors33 and glucagon-like peptide-1 receptor agonists have established themselves as guideline-recommended therapies for improving cardiovascular outcomes in patients with T2DM.34 Here, SLC5A2 is linked to type 2 diabetes mellitus.